Replies to post #332025 on Avid Bioservices Inc (CDMO)

[biopharm]

Nice update and biomarkers / protein pathways are key to FDA approval

The primary endpoint of the study will assess the antitumor activity of the combination, as well as safety and tolerability. In addition, other endpoints include evaluating drug levels, the effect of treatment on target proteins, and an exploratory analysis using Oncologie’s proprietary RNA biomarker signatures.

https://oncologie.international/oncologie-announces-first-patient-enrolled-in-global-phase-2-study-of-bavituximab-plus-keytruda-pembrolizumab-for-advanced-gastric-or-gastroesophageal-cancer/

Now what does Avid BOD say with Omeros and a FULL pipeline filled with PS Targeting / protein pathways targeted ....and those EXOSOMES for early cancer detection at New England Peptides that Ampersand just backed with $$$$$

Avid BOD and Ampersand Capital not being to helpful in seeking answers....maybe they are to busy with TriPharm another CDMO they are seeking business for